Ability Biologics

Ability Biologics is a top-tier cell-targeting company. The company is committed to developing innovative, targeted, and immunomodulatory biologics to address unmet medical needs of patients with cancer and autoimmune diseases. The AbiLeap™ discovery engine combines an artificial intelligence (AI) platform with a large database of antibody-antigen interactions, aggregating vast amounts of data from both public and private sources. This enables the company to tackle long-standing challenges by generating logic-gated fully human antibodies, allowing it to target specific tissues and cells based on conditions such as pH, temperature, or the presence of certain metabolites that define the local microenvironment.